11:50 AM EST - Neovasc Inc. : Announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation to the Neovasc Reducer™, a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. Neovasc Inc.
shares T.NVCN are trading up $0.89 at $4.06.
